Are there any blood screening tests available for cancer detection, particularly for patients with a high risk of cancer due to family history or genetic mutations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Blood Screening for Cancer Detection

Yes, blood screening tests for cancer exist, but they are currently limited to specific contexts: PSA testing for prostate cancer in high-risk individuals (particularly those with BRCA2 mutations or strong family history), and emerging multi-cancer early detection tests that are still under investigation and not yet part of standard screening guidelines. 1, 2

Established Blood-Based Cancer Screening

Prostate-Specific Antigen (PSA) Testing

PSA testing is the only widely established blood screening test for cancer detection, specifically for prostate cancer in defined high-risk populations. 1, 2

High-Risk Populations Warranting PSA Screening:

  • Men with BRCA2 mutations should begin PSA screening at age 40, as they have a 2-6 fold increased risk of aggressive prostate cancer with significantly reduced survival compared to non-carriers 3, 2

  • Men with BRCA1 mutations should consider PSA screening starting at age 40 3, 2

  • Men with other germline mutations (ATM, CHEK2, PALB2, mismatch repair genes) should begin screening at age 40 2

  • Men with a strong family history (brother, father, or multiple family members diagnosed before age 60) should begin screening at age 40-45 1

  • Men with a single first-degree relative diagnosed before age 60 should begin screening at age 45 1

Important Caveats About PSA Screening:

  • Baseline PSA value is a stronger predictive factor than family history or race alone 3, 2

  • BRCA2 carriers with PSA >3.0 ng/mL have significantly higher positive predictive value for detecting intermediate/high-grade cancer (2.4% vs 0.7%; P=.04) 3, 2

  • Screening intervals of 1-2 years are recommended rather than annual testing to reduce unnecessary biopsies while retaining 87-95% of life-years saved 1

Genetic Testing for Cancer Risk Assessment

Germline genetic testing is a form of blood screening that identifies inherited cancer susceptibility, though it detects risk rather than active cancer. 3, 2

Recommended Genetic Testing Scenarios:

  • Individuals with personal history of prostate cancer and ≥1 close blood relatives with breast cancer (age ≤50) or ovarian cancer, or ≥2 relatives with breast, pancreatic, or prostate cancer (Gleason ≥7) 3

  • Patients with pancreatic cancer should undergo universal genetic testing regardless of family history, as typical clinical factors poorly predict mutation carriers 3

  • Testing should include at minimum: BRCA1, BRCA2, ATM, CHEK2, PALB2, MLH1, MSH2, MSH6, PMS2 2

  • First-degree relatives of patients with pancreatic cancer may benefit from testing, though testing the affected patient is preferred 3

Emerging Multi-Cancer Early Detection Tests

Blood-based multi-cancer early detection tests are under investigation but are NOT currently recommended for routine screening. 4, 5

Current Status:

  • Multiple tests (CancerSEEK, Galleri, PanSeer) are in clinical trials showing high specificity in preliminary findings 5

  • These tests have potential to detect cancers for which no screening currently exists, which account for 71% of cancer deaths 4

  • However, it remains unclear if their use can reduce cancer mortality, and issues of cost-effectiveness, false-positives, and false-negatives remain unresolved 4

  • These tests are not yet validated for clinical use and should not be used outside of research protocols 5, 6

Traditional Tumor Biomarkers

Traditional tumor biomarkers have limited sensitivity and specificity for cancer screening in asymptomatic individuals. 7

  • Most tumor markers (CA-125, CEA, AFP, etc.) are used for monitoring known cancer rather than screening 7

  • The risk of overdiagnosis remains a particular concern, whereby lesions of no clinical consequence may be detected, creating difficult management decisions 7

Critical Pitfalls to Avoid

  • Do not confuse somatic tumor sequencing with germline testing - somatic tests are not designed or validated for germline assessment 2

  • If germline mutation is suspected from tumor testing, refer for genetic counseling and dedicated germline testing 2

  • Do not screen with PSA in average-risk men without considering individual risk factors and shared decision-making 1

  • Do not use multi-cancer detection tests outside of clinical trials - they lack validation for clinical decision-making 4, 5

References

1
Guideline

Prostate Cancer Screening Guidelines for High-Risk Individuals

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2
Guideline

Germline Mutations and Prostate Cancer Risk

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Research

Novel blood-based early cancer detection: diagnostics in development.

The American journal of managed care, 2020

7
Research

Early detection of cancer: past, present, and future.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015

Related Questions

Is there a single test to detect cancer anywhere in the body?
What role do blood tests play in cancer screening?
Is a blood test alone sufficient for cancer screening?
What are the benefits and limitations of the GRAIL screening blood test for early cancer detection in adults with a higher risk of cancer, such as those with a family history of cancer or certain genetic mutations?
Can laboratory tests (labs) alone confirm the presence of cancer?
Can a gay male patient with a history of low transsphincteric anal fistula and previous fistulotomy safely engage in receptive anal intercourse?
What is the recommended initial management for a nonpregnant adult female presenting with symptoms of uncomplicated cystitis via Telehealth?
What is the recommended course of action for a patient with a history of spinal stenosis or previous back surgery presenting with symptoms of cauda equina syndrome, including severe low back pain, numbness or tingling in the legs, weakness or paralysis, and loss of bladder and bowel control?
Can pelvic care therapy, including pelvic floor physical therapy, improve the enjoyment of anal sex in a gay male patient with a history of low transsphincteric anal fistula and previous fistulotomy?
How is resistant hypertension, particularly in older adults with chronic kidney disease, obesity, or sleep apnea, best managed?
Why do some postpartum women, particularly those with conditions like hypothyroidism (underactive thyroid) or polycystic ovary syndrome (PCOS), experience difficulty losing weight, and does breastfeeding play a role in their weight loss?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question